N-3 polyunsaturated fatty acids for cardiovascular risk

This article provides a review of the data surrounding these trials and discusses the differing results of the two trials. There are key differences in the design of the two trials, the most notable is the use of mineral oil in the REDUCE-IT trial, which was potentially a nonneutral comparator. Additionally, both trials showed an increase in the incidence of atrial fibrillation. With the unclear benefit of OM3FA supplementation and possibility of harm, the current data suggest that the risk of routine use of OM3FA outweighs the possibility of reduction in risk of cardiovascular events.
Source: Current Opinion in Cardiology - Category: Cardiology Tags: LIPIDS AND EMERGING RISK FACTORS: Edited by Dimitri P. Mikhailidis and Debabrata Mukherjee Source Type: research